The number of class-action lawsuits claiming securities fraud committed by life sciences companies leveled off last year, but a new trend emerged — unlike in the past, when most suits targeted small-cap companies, more cases involved drug or device makers with market caps of $500 million or more.

A total of 86 class action securities lawsuits were filed against life sciences companies in 2018, a drop from 88 lawsuits filed the year before. Even so, this still represented a 352 percent rise from 19 such lawsuits that were filed in 2013, according to the Dechert law firm, which conducted the latest analysis.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy